Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges

References

• Archie V, Kauh J, Jones DV Jr, Cruz V, Karpeh MS Jr, Thomas CR Jr. Gastric cancer: standards for the 21st century. Crit. Rev. Oncol. Hematol.57(2), 123–131 (2006).
   PubMed Web of Science ®Google Scholar
• Gallo A, Cha C. Updates on esophageal and gastric cancers. World J. Gastroenterol.12(20), 3237–3242 (2006).
   PubMed Web of Science ®Google Scholar
• Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov.5(3), 219–234 (2006).
   PubMed Web of Science ®Google Scholar
• Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu. Rev. Pharmacol. Toxicol.39, 361–398 (1999).
   PubMed Web of Science ®Google Scholar
• Deuchars KL, Ling V. P-glycoprotein and multidrug resistance in cancer chemotherapy. Semin. Oncol.16(2), 156–165 (1989).
   PubMed Web of Science ®Google Scholar
• Zaman GJ, Versantvoort CH, Smit JJ et al. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res.53(8), 1747–1750 (1993).
   PubMed Web of Science ®Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl Cancer Inst.92(16), 1295–1302 (2000).
   PubMed Web of Science ®Google Scholar
• Litman T, Brangi M, Hudson E et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J. Cell Sci.113(Pt 11), 2011–2021 (2000).
   PubMed Web of Science ®Google Scholar
• Ross DD, Yang W, Abruzzo LV et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl Cancer Inst.91(5), 429–433 (1999).
   PubMed Web of Science ®Google Scholar
• Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene22(47), 7340–7358 (2003).
   PubMed Web of Science ®Google Scholar
• Varadhachary G, Ajani JA. Preoperative and adjuvant therapies for upper gastrointestinal cancers. Expert Rev. Anticancer Ther.5(4), 719–725 (2005).
   PubMed Web of Science ®Google Scholar
• Ajani JA. Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. Expert Opin. Pharmacother.7(12), 1627–1631 (2006).
   PubMed Web of Science ®Google Scholar
• Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett.580(12), 2903–2909 (2006).
   PubMed Web of Science ®Google Scholar
• Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, Scheper RJ. Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr. Opin. Oncol.12(6), 550–556 (2000).
   PubMed Web of Science ®Google Scholar
• Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl Acad. Sci. USA89(7), 3070–3074 (1992).
   PubMed Web of Science ®Google Scholar
• Minagawa Y, Kigawa J, Itamochi H, Terakawa N. The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer. Hum. Cell14(3), 237–243 (2001).
   PubMedGoogle Scholar
• Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM. The cytoplasmic trafficking of DNA topoisomerase IIα correlates with etoposide resistance in human myeloma cells. Exp. Cell Res.295(2), 421–431 (2004).
   PubMed Web of Science ®Google Scholar
• Cai Y, Wu MH, Xu-Welliver M, Pegg AE, Ludeman SM, Dolan ME. Effect of O6-benzylguanine on alkylating agent-induced toxicity and mutagenicity. In Chinese hamster ovary cells expressing wild-type and mutant O6-alkylguanine-DNA alkyltransferases. Cancer Res.60(19), 5464–5469 (2000).
   PubMed Web of Science ®Google Scholar
• Spiro TP, Gerson SL, Liu L et al. O6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res.59(10), 2402–2410 (1999).
   PubMed Web of Science ®Google Scholar
• Koberle B, Masters JR, Hartley JA, Wood RD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr. Biol.9(5), 273–276 (1999).
   PubMed Web of Science ®Google Scholar
• Kavallaris M, Kuo DY, Burkhart CA et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J. Clin. Invest.100(5), 1282–1293 (1997).
   PubMed Web of Science ®Google Scholar
• Giannakakou P, Sackett DL, Kang YK et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem.272(27), 17118–17125 (1997).
   PubMed Web of Science ®Google Scholar
• Eischen CM, Kottke TJ, Martins LM et al. Comparison of apoptosis in wild-type and Fas-resistant cells: chemotherapy-induced apoptosis is not dependent on Fas/Fas ligand interactions. Blood90(3), 935–943 (1997).
   PubMed Web of Science ®Google Scholar
• Landowski TH, Shain KH, Oshiro MM, Buyuksal I, Painter JS, Dalton WS. Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation. Blood94(1), 265–274 (1999).
   PubMed Web of Science ®Google Scholar
• Shain KH, Landowski TH, Buyuksal I, Cantor AB, Dalton WS. Clonal variability in CD95 expression is the major determinant in Fas-medicated, but not chemotherapy-medicated apoptosis in the RPMI 8226 multiple myeloma cell line. Leukemia14(5), 830–840 (2000).
   PubMed Web of Science ®Google Scholar
• Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med.2(5), 574–577 (1996).
   PubMed Web of Science ®Google Scholar
• Fulda S, Susin SA, Kroemer G, Debatin KM. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res.58(19), 4453–4460 (1998).
   PubMed Web of Science ®Google Scholar
• Antoku K, Liu Z, Johnson DE. Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia11(10), 1665–1672 (1997).
   PubMed Web of Science ®Google Scholar
• Schurmann A, Mooney AF, Sanders LC et al. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol. Cell. Biol.20(2), 453–461 (2000).
   PubMed Web of Science ®Google Scholar
• Minn AJ, Rudin CM, Boise LH, Thompson CB. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood86(5), 1903–1910 (1995).
   PubMed Web of Science ®Google Scholar
• Zhang Y, Fujita N, Tsuruo T. p21Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int. J. Cancer83(6), 790–797 (1999).
   PubMed Web of Science ®Google Scholar
• Nuessler V, Stotzer O, Gullis E et al. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines. Leukemia13(11), 1864–1872 (1999).
   PubMed Web of Science ®Google Scholar
• Houghton JM Wang T. Tumors of the stomach. In: Sleisenger & Fordtran’s Gastrointestinal and Liver Disease (8th Edition). Feldman M, Friedman L, Brandt LJ (Eds). Saunders Elsevier, PA, USA 1139–1156 (2006).
   Google Scholar
• Wallner J, Depisch D, Gsur A, Gotzl M, Haider K, Pirker R. MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer71(3), 667–671 (1993).
   PubMed Web of Science ®Google Scholar
• Gurel S, Yerci O, Filiz G et al. High expression of multidrug resistance-1 (MDR-1) and its relationship with multiple prognostic factors in gastric carcinomas in patients in Turkey. J. Int. Med. Res.27(2), 79–84 (1999).
   PubMed Web of Science ®Google Scholar
• Choi JH, Lim HY, Joo HJ et al. Expression of multidrug resistance-associated protein1, P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br. J. Cancer86(10), 1578–1585 (2002).
   PubMed Web of Science ®Google Scholar
• Tomonaga M, Oka M, Narasaki F et al. The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers. Jpn. J. Cancer Res.87(12), 1263–1270 (1996).
   PubMedGoogle Scholar
• Fan K, Fan D, Cheng LF, Li C. Expression of multidrug resistance-related markers in gastric cancer. Anticancer Res.20(6C), 4809–4814 (2000).
   PubMed Web of Science ®Google Scholar
• Yeh KH, Chen CL, Shun CT et al. Relatively low expression of multidrug resistance-1 (MDR-1) and its possible clinical implication in gastric cancers. J. Gastroenterol.26(4), 274–278 (1998).
   Web of Science ®Google Scholar
• Yamauchi M, Kumazawa H, Satta T et al. Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining. Eur. J. Cancer28A(8–9), 1422–1427 (1992).
   PubMed Web of Science ®Google Scholar
• Endo K, Maehara Y, Ichiyoshi Y et al. Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer77(Suppl. 8), 1681–1687 (1996).
   PubMed Web of Science ®Google Scholar
• Lacueva J, Perez-Ramos M, Soto JL et al. Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR. Histopathology46(4), 389–395 (2005).
   PubMed Web of Science ®Google Scholar
• Schipper DL, Wagenmans MJ, Peters WH, Wils JA, Wagener DJ. Glutathione S-transferases and iododeoxyuridine labelling index during chemotherapy of gastric cancer. Anticancer Res.20(3A), 1705–1710 (2000).
   PubMed Web of Science ®Google Scholar
• Monden N, Abe S, Sutoh I, Hishikawa Y, Kinugasa S, Nagasue N. Prognostic significance of the expressions of metallothionein, glutathione-S-transferase-Π, and P-glycoprotein in curatively resected gastric cancer. Oncology54(5), 391–399 (1997).
   PubMed Web of Science ®Google Scholar
• Okuyama T, Maehara Y, Endo K et al. Expression of glutathione S-transferase-Π and sensitivity of human gastric cancer cells to cisplatin. Cancer74(4), 1230–1236 (1994).
   PubMed Web of Science ®Google Scholar
• Filomeni G, Aquilano K, Rotilio G, Ciriolo MR. Glutathione-related systems and modulation of extracellular signal-regulated kinases are involved in the resistance of AGS adenocarcinoma gastric cells to diallyl disulfide-induced apoptosis. Cancer Res.65(24), 11735–11742 (2005).
   PubMed Web of Science ®Google Scholar
• Niitsu Y, Takahashi Y, Saito T et al. Serum glutathione-S-transferase-Π as a tumor marker for gastrointestinal malignancies. Cancer63(2), 317–323 (1989).
   PubMed Web of Science ®Google Scholar
• Peters WH, Wormskamp NG, Thies E. Expression of glutathione S-transferases in normal gastric mucosa and in gastric tumors. Carcinogenesis11(9), 1593–1596 (1990).
   PubMed Web of Science ®Google Scholar
• Kodera Y, Akiyama S, Isobe K et al. Expression of Π-glutathione S-transferase gene (GSTP1) in gastric cancer: lack of correlation with resistance against cis-diamminedichloroplatinum (II). Eur. J. Cancer30A(14), 2158–2162 (1994).
   PubMed Web of Science ®Google Scholar
• Kim R, Ohi Y, Inoue H, Toge T. Expression and relationship between topoisomerase I and II α genes in tumor and normal tissues in esophageal, gastric and colon cancers. Anticancer Res.19(6B), 5393–5398 (1999).
   PubMed Web of Science ®Google Scholar
• Coleman LW, Bronstein IB, Holden JA. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-α and p53 in gastric carcinomas. Anticancer Res.21(2A), 1167–1172 (2001).
   PubMed Web of Science ®Google Scholar
• Tanner M, Hollmen M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol.16(2), 273–278 (2005).
   PubMed Web of Science ®Google Scholar
• Kellner U, Hutchinson L, Seidel A et al. Decreased drug accumulation in a mitoxantrone-resistant gastric carcinoma cell line in the absence of P-glycoprotein. Int. J. Cancer71(5), 817–824 (1997).
   PubMed Web of Science ®Google Scholar
• Nagai S, Yamauchi M, Andoh T et al. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J. Surg. Oncol.59(2), 116–124 (1995).
   PubMed Web of Science ®Google Scholar
• Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S. The evaluation of gastric cancer sensitivity to 5-FU/CDDP in terms of induction of apoptosis: time- and p53 expression-dependency of anti-cancer drugs. Oncol. Rep.14(3), 609–615 (2005).
   PubMed Web of Science ®Google Scholar
• Cascinu S, Graziano F, Del Ferro E et al. Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer83(9), 1917–1922 (1998).
   PubMed Web of Science ®Google Scholar
• Yeh KH, Shun CT, Chen CL et al. Overexpression of p53 is not associated with drug resistance of gastric cancers to 5-fluorouracil-based systemic chemotherapy. Hepatogastroenterology46(25), 610–615 (1999).
   PubMedGoogle Scholar
• Muller M, Wilder S, Bannasch D et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med.188(11), 2033–2045 (1998).
   PubMed Web of Science ®Google Scholar
• Ning H, Li T, Zhao L et al. TRF2 promotes multidrug resistance in gastric cancer cells. Cancer Biol. Ther.5(8), 950–956 (2006).
   PubMed Web of Science ®Google Scholar
• Hao Z, Li X, Qiao T, Du R, Hong L, Fan D. CIAPIN1 confers multidrug resistance by upregulating the expression of MDR-1 and MRP-1 in gastric cancer cells. Cancer Biol. Ther.5(3), 261–266 (2006).
   PubMed Web of Science ®Google Scholar
• Yin F, Du Y, Hu W et al. Mad2β, an alternative variant of Mad2 reducing mitotic arrest and apoptosis induced by adriamycin in gastric cancer cells. Life Sci.78(12), 1277–1286 (2006).
   PubMed Web of Science ®Google Scholar
• Du Y, Yin F, Liu C et al. Depression of MAD2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway. Biochem. Biophys. Res. Commun.345(3), 1092–1098 (2006).
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhai H, Wang X et al. Multidrug-resistance-associated protein MGr1-Ag is identical to the human 37-kDa laminin receptor precursor. Cell Mol. Life Sci.59(9), 1577–1583 (2002).
   PubMed Web of Science ®Google Scholar
• Shi Y, Han Y, Wang X et al. MGr1-Ag is associated with multidrug-resistant phenotype of gastric cancer cells. Gastric Cancer5(3), 154–159 (2002).
   PubMedGoogle Scholar
• Sun L, Shi Y, Guo C et al. Regulation of multidrug resistance by MGr1-antigen in gastric cancer cells. Tumour Biol.27(1), 27–35 (2006).
   PubMedGoogle Scholar
• Zhao Y, You H, Liu F et al. Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett.185(2), 211–218 (2002).
   PubMed Web of Science ®Google Scholar
• Du J, Pan Y, Shi Y et al. Overexpression and significance of prion protein in gastric cancer and multidrug-resistant gastric carcinoma cell line SGC7901/ADR. Int. J. Cancer113(2), 213–220 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang YM, Zhao YQ, Pan YL et al. Effect of ZNRD1 gene antisense RNA on drug resistant gastric cancer cells. World J. Gastroenterol.9(5), 894–898 (2003).
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhang Y, Zhao Y et al. Overexpression of ZNRD1 promotes multidrug-resistant phenotype of gastric cancer cells through upregulation of P-glycoprotein. Cancer Biol. Ther.3(4), 377–381 (2004).
   PubMed Web of Science ®Google Scholar
• Hong L, Qiao T, Han Y et al. ZNRD1 mediates resistance of gastric cancer cells to methotrexate by regulation of IMPDH2 and Bcl-2. Biochem. Cell. Biol.84(2), 199–206 (2006).
   PubMed Web of Science ®Google Scholar
• Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, Tsuruo T. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res.56(12), 2823–2826 (1996).
   PubMed Web of Science ®Google Scholar
• Sagara N, Katoh M. Mitomycin C resistance induced by TCF-3 overexpression in gastric cancer cell line MKN28 is associated with DT-diaphorase down-regulation. Cancer Res.60(21), 5959–5962 (2000).
   PubMed Web of Science ®Google Scholar
• Shi Y, Hu W, Yin F et al. Regulation of drug sensitivity of gastric cancer cells by human calcyclin-binding protein (CacyBP). Gastric Cancer7(3), 160–166 (2004).
   PubMedGoogle Scholar
• Shi Y, Zhai H, Wang X et al. Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. Exp. Cell Res.296(2), 337–346 (2004).
   PubMed Web of Science ®Google Scholar
• Du J, Shi Y, Pan Y et al. Regulation of multidrug resistance by ribosomal protein l6 in gastric cancer cells. Cancer Biol. Ther.4(2), 242–247 (2005).
   PubMed Web of Science ®Google Scholar
• Park DJ, Lenz HJ. Determinants of chemosensitivity in gastric cancer. Curr. Opin. Pharmacol.6(4), 337–344 (2006).
   PubMed Web of Science ®Google Scholar
• Gyorffy B, Serra V, Materna V et al. Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs. Melanoma Res.16(2), 147–155 (2006).
   PubMed Web of Science ®Google Scholar
• Mimori K, Sadanaga N, Yoshikawa Y et al. Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br. J. Cancer94(12), 1894–1897 (2006).
   PubMed Web of Science ®Google Scholar
• Kamoshida S, Suzuki M, Shimomura R et al. Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br. J. Cancer96(2), 277–283 (2007).
   PubMed Web of Science ®Google Scholar
• Hofler H, Langer R, Ott K, Keller G. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Adv. Exp. Med. Biol.587, 115–120 (2006).
   PubMedGoogle Scholar
• Kubota T, Weisenthal L. Chemotherapy sensitivity and resistance testing: to be “standard” or to be individualized, that is the question. Gastric Cancer9(2), 82–87 (2006).
   PubMedGoogle Scholar